DIA’s Conference on clinical trial endpoints will bring together key stakeholders to address critical questions and generate potential solutions to challenges associated with determining study endpoints and outcomes. The 2018 Conference will examine global strategies for selecting study endpoints, and the impact of study endpoints during analysis of clinical evidence in the various types of drug approval processes.
While we continue to develop this program, check out our Agenda from 2016 to see what's in store!
This program has been developed in collaboration with the Study Endpoints Community.
Who should attend?
Professionals involved in:
- Clinical Trials
- Health technology involved in
- Setting, executing, or evaluating endpoint strategy for drug approval, labeling, promotion, translational science, and market access
René Allard, PhD • Public Disclosure Lead
Grünenthal GmbH, Germany
Emuella Flood • Senior Director, Patient-Reported Outcomes
ICON, plc., United States
J. Jason Lundy, PhD • Principal
Outcometrix, United States
Matthew Reaney •
Sanofi, United Kingdom
Ashley F. Slagle, PhD, MS • Principal, Scientific and Regulatory Consulting
Aspen Consulting, LLC, United States
Keith W. Wenzel • Senior Director, Solution Incubator
PAREXEL, United States
Michael Lees • Head of Value, Evidence and Portfolio Strategy – EUCAN
Takeda Pharmaceuticals International GmbH, Switzerland